Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 1, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 3,000,000 ordinary shares of 25 pence each.
- Purchase Price: 1,390.94 pence per share.
- Treasury Shares Held: 211,769,678 shares (post-transaction).
- Shares in Issue: 5,776,266,663 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares and the increase in Treasury stock following the repurchase on November 1, 2006. This action was executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the 3,000,000 share repurchase based on the disclosed price of 1,390.94 pence.
- Confirm the updated total share capital structure (5,776,266,663 shares in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authority.